{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T09:42:21Z","timestamp":1768642941635,"version":"3.49.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012400","name":"Sigma Theta Tau International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.clml.2017.08.100","type":"journal-article","created":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T01:47:30Z","timestamp":1502761650000},"page":"884-888","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5297-9685","authenticated-orcid":false,"given":"David","family":"Qualls","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5011-2575","authenticated-orcid":false,"given":"Andrew","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuli","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry","family":"Collier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ephraim","family":"Hochberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy T.","family":"Batchelor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachariah","family":"DeFilipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.08.100_bib1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2008.16.8021","article-title":"Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 \u2013 the Southwest Oncology Group","volume":"27","author":"Bernstein","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.08.100_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdl327","article-title":"Incidence and risk factors of central nervous system recurrence in aggressive lymphoma\u2013a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)","volume":"18","author":"Boehme","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.08.100_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00277-005-1096-3","article-title":"Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system","volume":"85","author":"Jahnke","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2017.08.100_bib4","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0959-8049(00)00171-4","article-title":"Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis","volume":"36","author":"Hollender","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2017.08.100_bib5","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1200\/JCO.2015.61.1236","article-title":"High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and secondary CNS involvement: final results of a multicenter phase II trial","volume":"33","author":"Ferreri","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.08.100_bib6","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3324\/haematol.2012.077917","article-title":"Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas","volume":"98","author":"Korfel","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.08.100_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3109\/10428194.2015.1026901","article-title":"Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan\/thiotepa-based conditioning and autologous stem cell transplant","volume":"57","author":"Oh","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.08.100_bib8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/10428194.2014.916800","article-title":"Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide","volume":"56","author":"Welch","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.08.100_bib9","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1182\/blood-2013-06-453084","article-title":"How I treat CNS lymphomas","volume":"122","author":"Rubenstein","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.08.100_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbmt.2011.07.006","article-title":"Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma","volume":"18","author":"Cote","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.08.100_bib11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/cncr.29023","article-title":"Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma","volume":"121","author":"Chen","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.08.100_bib12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bbmt.2016.09.024","article-title":"A\u00a0comprehensive assessment of toxicities in patients with central nervous system lymphoma undergoing autologous stem cell transplantation using thiotepa, busulfan, and cyclophosphamide conditioning","volume":"23","author":"Scordo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.08.100_bib13","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.08.100_bib14","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/archneur.1997.00550190044013","article-title":"Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients","volume":"54","author":"Bollen","year":"1997","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clml.2017.08.100_bib15","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.1996.14.11.3036","article-title":"Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies","volume":"14","author":"van Besien","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.08.100_bib16","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/cncr.30695","article-title":"High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission","volume":"123","author":"DeFilipp","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.08.100_bib17","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/bjh.12451","article-title":"Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement","volume":"162","author":"Maziarz","year":"2013","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017307644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017307644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:36Z","timestamp":1761870696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017307644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S2152265017307644"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.08.100","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.08.100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}